Merck & Co to Cut Jobs at Newly Acquired Cubist

US drugmaker Merck & Co, the new parent company of Cubist Pharmaceuticals, has informed employees of plans to eliminate the company's 120-employee drug discovery department.

The job cuts will affect about 20% of Cubist's around 600 employees in the US state of Massachusetts.

New Jersey-based Merck completed the acquisition of Cubist on Jan. 22 for $9.5 billion. A spokesperson for the drugs giant told the Boston Business Journal that the "difficult decision" came as Merck was reviewing its assets, which includes a 450-employee research center in Boston and a Boston-based business development center.

The spokesperson said Merck remains committed to the development of antibiotic drugs, adding that an unspecified number of such products still in pre-clinical testing will continue development in other sites, and that all of Cubist's drugs in clinical trials will continue to be developed.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read